App-Quantinova.ai

The impact of induction chemoimmunotherapy (iCIT) on the immune status of patients (pts.) with non-small cell lung cancer (NSCLC).

Elena Yurievna Zlatnik - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Outcomes of chemoradiotherapy for stage III non-small-cell lung cancer in Brazil.

Juliano Ce Coelho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Retrospective study of patients with malignant pleural mesothelioma treated and followed at Instituto Oncologico Henry Moore (IOHM).

Mariana Abal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

Cisplatin

The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.

Irene Guijarro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Cisplatin

45 Gy versus 54 Gy of accelerated hyperfractionated thoracic radiotherapy for patients with limited-stage small-cell lung cancer.

Kanji Matsuura - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Cisplatin

Randomized phase II trial of intercalated gefitinib (G) and pemetrexed/cisplatin (Pem/Cis) for never-smokers with chemo-naive stage IIIB/IV lung adenocarcinoma (LADC).

Jin Soo Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cisplatin

ERCC1 expression in tumor tissue as biomarker of outcomes of oral vinorelbine-cisplatin (oVP) combination in metastatic squamous cell lung cancer (SqLC): A prospective studyGGCP 052/12.

Carolina Pena - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cisplatin

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC).

Kelvin Young - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

The relationship between carnitine pharmacokinetics and fatigue in cancer patients treated with cisplatin-containing chemotherapy.

Tatsuhiko Kashii - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mesothelioma

Cisplatin

Safety of histamine H2 blocker concomitant administration in patients treated with high dose methotrexate regimen.

Yun Jung Choi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Cisplatin

Evaluation of chemotherapy-induced nausea and vomiting (CINV) events and associated resource utilization for CINV in patients(pts) treated with highly emetogenic chemotherapy (HEC) and carboplatin (Carbo) and palonosetron (palo)-based anti-emetic regimens.

Robert B. Geller - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chemotherapy-induced nausea and vomiting

Cisplatin

Changes in the detection and recognition thresholds of three basic tastes in patients with non-small cell lung cancer receiving cisplatin- and paclitaxel-based chemotherapy and its association with nutritional and quality of life parameters.

Jenny Turcott - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.

Lee Steven Schwartzberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Cisplatin

A new agent, liposomal cisplatin, in the treatment of relapsed or metastatic childhood solid tumors: Toxicity and clinical effectiveness.

Nurdan Tacyildiz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Cisplatin

Everolimus/sorafenib combination in the treatment of refractory pediatric osteosarcomas: Single center experience.

Alexander A. Fedenko - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Osteosarcoma

Cisplatin

Vinorelbine-based chemotherapy in metastatic epithelioid sarcoma.

Camille Tlemsani - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Epithelioid sarcoma

Cisplatin

Exploring the utility of exosomal HER receptor dimerization as a resistance mechanism in NSCLC.

Myria Galazi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Lung tumorspheres as a platform for testing new therapeutic strategies in lung cancer.

Ester Munera-Maravilla - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Cisplatin

Atezolizumab as 1L Therapy in Cisplatin-Ineligible Locally Advanced/Metastatic Urothelial Carcinoma: IMvigor210 Cohort 1

Arjun Vasant Balar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Cisplatin

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

Helen Mackay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

Cisplatin

Filters

3952 Abstracts